Business
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026
CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, March 19, 2026 at 4:30 PM ET to discuss financial results for the fourth quarter ended December 31, 2025, and recent business progress. Conference Call and Webcast Information: Dat
About this update from Relmada Therapeutics, Inc.
[{"type":"image","alt":"Relmada Therapeutics","displaySize":"","headline":null,"caption":"Relmada Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/1e6b0a87f8dab0f1d062695dd08847ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0268YsqVciKwgjFbGEosKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1e6b0a87f8dab0f1d062695dd08847ff","width":300,"height":75}},"lazy":false},{"type":"text","content":"CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, March 19, 2026 at 4:30 PM ET to discuss financial results for the fourth quarter ended December 31, 2025, and recent business progress.","length":455,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast Information:","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Date: Thursday, March 19, 2026 at 4:30 PM ET","length":44,"tagName":"p"}]},{"val":[{"type":"text","content":"Participant Dial-in (US): 1-877-407-0792","length":40,"tagName":"p"}]},{"val":[{"type":"text","content":"Participant Dial-in (International): 1-201-689-8263","length":51,"tagName":"p"}]},{"val":[{"type":"text","content":"Webcast Access: Click Here","length":26,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":161,"olType":false},{"type":"text","content":"A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.","length":144,"tagName":"p"},{"type":"text","content":"About Relmada Therapeutics, Inc.Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.","length":347,"tagName":"p"},{"type":"text","content":"For more information, visit www.relmada.com","length":48,"tagName":"p"},{"type":"text","content":"Investor Contact:Br...